The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research, focusing on uncovering the causes of cancer and reprogramming cancer cells.

We dedicate ourselves to delivering tailored, minimally toxic treatments to patients. Our mission is to eradicate cancer by bridging the gap between lab science and the patient. Through our collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research.

Since our inception in 1976, The Foundation has awarded more than $80 million to support the work of more than 200 researchers across the globe.
For 36 years, the Samuel Waxman Cancer Research Foundation has been a pioneer in tackling cancer at its root, designing treatments to correct abnormal genes that cause cancer. Our mission is twofold: to deliver less toxic treatments and to bring faster cures to patients. Enhancing the quality of life for cancer survivors is an important part of the research that we fund, which is why our scientists are looking at the biology of the disease and investigating ways to stop cancer from spreading.

Although current treatment options like chemotherapy and radiation are effective against some cancers, they are not effective against all cancers. Indeed, the harsh treatment options today can leave many survivors with long-term survivorship issues. The Waxman Foundation believes there must be a better way.

Our funded investigators include some of the best scientific minds in cancer research. We support ongoing multi-disciplinary innovative research projects by highly-respected teams of scientists who like to think out-of-the-box in solving a problem. Because their proposals are often considered early “high risk” by institutions like the National Cancer Institute, these brilliant researchers might not receive funding for their new approaches to kill cancer cells. This is limiting innovative research more now than ever due to cutbacks in government funding. Cancer scientists are placed in a defensive position.

The good news is that the Waxman Foundation has taken risks to invest in these researchers, many of whom have gone on to leverage their initial Waxman Foundation seed grant to secure millions of dollars from the National Cancer Institute – which deemed their projects too risky in the first place. Ironic? Perhaps. But this is the unique niche that the Foundation fulfills in cancer research. We’ve been doing it for 36 years and are very proud of what we have been able to accomplish together with your help. Thank you for joining us as we envision a world without cancer.
**YEAR IN REVIEW**

**January 1, 2012**
SWCRF invites cancer centers across the U.S. to apply for research grants

**February 3, 2012**
Marcia and David Lavipour and their niece Jennifer Schwab Yanowitz host the Quest to Cure CML, raising nearly $40,000

**March 15, 2012**
Deadline to submit new grant proposals

**April 1, 2012**
Deadline to submit continuing grant proposals

**October 20 - 24, 2012**
The 13th International Conference on Differentiation Therapy: Differentiation Therapy and Advances in Cancer in Suzhou, China

**May 15 & 16, 2012**
Annual Scientific Review was held in New York and attended by 50 scientists from across the globe

**May 16, 2012**
The Scientific Symposium was held at the Alexandria Center giving donors the opportunity to meet the scientists, learn more about where their money goes and the research undertaken

**June 25, 2012**
72 golfers gather at Old Oaks Country Club, despite the rainy day, and raised over $110,000

**August 11, 2012**
The 8th Annual Hamptons Happening honored Jean-Georges and raised over $250,000

**November 4, 2012**
Although the ING NYC Marathon was canceled, Team Waxman still raised over $35,000 for the Foundation

**November 15, 2012**
Collaborating for a Cure’s 15th Annual Gala honored Dale and Peter Claman and Carmen Marc Valvo. We brought back a few of our original collaborators, Warren Haynes and Gregg Allman along with friend Peter Frampton, and raised over $3 million.
YOUR INVESTMENT IN WHAT WE DO

The SWCRF funds cancer research projects that have promise to make tangible advances against the cancer problem that sadly will be diagnosed in half of the men and a third of the women in the United States. Our research impacts all types of cancer. Through the annual rigorous scientific review, and with your financial support, we support critical research by leading scientists. How is the SWCRF furthering cancer research?

• We finance individual grants to enable innovative researchers to uncover new strategies to combat cancer.

• We organize an Institute without Walls to enable scientific teams to work more effectively and rapidly.

• We foster collaboration among scientists across the globe in diverse disciplines. Their collaboration is made possible through the support of our donors.

• We support “high risk” research that holds great promise to move from the laboratory bench to the cancer clinic.

• We support researchers in epigenetic therapy who will reprogram the cancer cell to behave like a normal cell.

• We supported research that led to the first successful example of differentiation therapy of a lethal malignancy, acute promyelocytic leukemia (APL). This has resulted in a unique collaboration with the Shanghai Institute of Hematology in China which has led to the cure of APL through differentiation therapy.

• We now want to build on this leukemia success to find ways to treat common cancers that are too often diagnosed in our society.
OUR RESEARCH is designed to create less toxic therapies for children through aging population. We have made great strides in cancer research for 36 years. We now want to do even more to reduce the cancer burden. To accomplish this, we must support at an even higher level those scientists selected by our competitive review process to receive our funding. This must be done as federal support for cancer research is being reduced. To learn how important our support is for our grantees, read their testimonials that follow.

BRAIN CANCER

Albert S. Baldwin Jr., Ph.D., University of North Carolina, Chapel Hill
Mark Lemmon, Ph.D., University of Pennsylvania
Kevan Shokat, Ph.D., University of California, San Francisco
William Weiss, M.D., Ph.D., University of California, San Francisco

Most drugs used to treat cancer do not work well in brain cancer. For example, in lung cancer, therapies that inhibit the receptor for one growth factor called the epidermal growth factor receptor (EGFR) can improve survival. Yet, these same drugs are ineffective in brain cancers, even though those cancers are dependent upon the same growth factors. Our work is supported by the SWCRF to find the basis for these different clinical responses. We hope that our research will lead to improved ways to treat all EGFR-driven cancers, including brain cancer.

CHILDHOOD AND YOUNG ADULT CANCER

John Crispino, Ph.D., Northwestern University

Our research is focused on identifying new therapies for leukemia. Our goal is to cure a rare leukemia, named acute megakaryoblastic leukemia. This is a cancer in which megakaryocytes, the cells that make platelets, grow excessively and fail to make platelets. With the support of the SWCRF, we have identified several small molecules that promote maturation of these abnormal cells and thus act as “differentiation therapy”. We are working with the SWCRF to develop these molecules into a new treatment for this leukemia. SWCRF also supports our efforts to better understand pediatric B-cell leukemia and to develop improved therapies for this type of cancer. Without the support of the SWCRF, our collaborative research to develop new cures for leukemia would not be possible. Thank you for the support of the Foundation!

Shai Izraeli, M.D., Tel Aviv University

One of our Leukemia discoveries (the JAK2-CRLF2-Interleukin 7 receptor mutations) has already led to clinical trials with newer drugs (JAK inhibitors). Another recent discovery is of a gene (ERG) whose increased expression converts normal blood stem cells into malignant leukemia stem cells. We now aim to decipher the precise mechanism by which ERG redirects normal into leukemic stem cells.
ALL CANCERS

Robert A. Weinberg, Ph.D., Whitehead Institute for Biomedical Research

Recent research has revealed that human tumors are often composed of small subpopulations of cancer cells exhibiting especially potent powers to invade, metastasize and find new tumors elsewhere in the body. These cancer stem cells (CSCs) also exhibit heightened powers to resist conventional therapies, generating residual disease after treatment and subsequent therapeutic relapse. Our work under the auspices of the SWCRF focuses on discovering signaling pathways that can be perturbed within CSCs, causing such cells to exit from the CSC state and undergo conversion into non-CSCs, thereby rendering them far more susceptible to conventional forms of therapy. If successful, such treatments should prove to be highly effective approaches in concert with conventional treatments, to yield durable clinical responses with tumors that hitherto have proven resistant to available treatments.

LYMPHOMA

Alexander MacKerrell, Ph.D., University of Maryland
Ari Melnick, M.D., Weill Cornell Medical Center
Gilbert Privé, Ph.D., University of Toronto

Research in our lab focuses on computer-aided drug design (CADD) methods for the discovery of new cancer drugs. Studies have targeted the development of inhibitors of gene expression that can overcome abnormal growth of cancer cells. One such inhibitor is called BCL6. Our work has led to the discovery of compounds with the potential to be developed into novel drugs to treat Diffuse Large B-cell Lymphoma (DLBCL). Our work has also led to the development of a new technology called CADD technology, Site-Identification by Ligand Competitive (SILCS) that will facilitate the design of drugs.

LIVER CANCER

Paul B. Fisher, Ph.D., Virginia Commonwealth University
Devanand Sarkar, MBBS, Ph.D., Virginia Commonwealth University

The SWCRF provides a critical service to the cancer research community. Its unique Institute without Walls requires scientists to collaborate and share their findings well before they publish their results. In this way, the Foundation supports some of the most promising areas of cancer research that have the potential for high reward. Indeed, SWCRF discoveries have already produced remarkable results in differentiation therapy of leukemia. This is one of the most notable successes in what is known as “bench to bedside research”. The Foundation is broadening its reach into the area of epigenetic therapy and this area holds great promise to improve cancer care. I have been very fortunate to be involved with the Foundation for over 30 years. I am grateful for this support that made my discoveries possible. Working with Devanand Sarkar, we have found new ways to regulate a protein that can restore normal gene expression and thereby treat late-stage hepatocellular (liver) carcinoma (HCC).
OVARIAN CANCER

Benjamin G. Neel, M.D., Ph.D., Ontario Cancer Institute
Garry P. Nolan, Ph.D., Stanford University School of Medicine

Ovarian cancer is the leading cause of gynecological morbidity/mortality. Current therapies significantly increase survival, but the vast majority of patients (70-90%) recur within five years and die of their disease. More effective therapies are needed to eliminate resistant cell populations. A small restricted population has the ability to initiate and sustain tumor growth are also resistant to current therapy. In much the same way as a weed cannot be eliminated only by removing its leaves, it is necessary to kill the “root” of the tumor, the “tumor-initiating cells (TIC)”. We are using a novel approach to rapidly identify TIC markers. We surveyed a large number (~400) of candidate markers to find those that can be used to purify TIC. Finally, we are using previously unrecognized technology called mass cytometry to find markers for the self-renewal/stem cell-like properties. Our results could lead to a general approach to diagnose and treat TIC, the root cause of ovarian and other types of cancer. Revolutionary technology is being developed by Garry Nolan which can be used in the early diagnosis of TIC.

LIVER CANCER

Josep M. Llovet, M.D., Mount Sinai School of Medicine

The SWCRF has been funding our Liver Cancer Program during the last 10 years. Liver cancer is the 3rd leading cause of cancer-related death globally (750,000 cases/yr.). By leading a broad network of international collaborators we have already reached these goals in our liver cancer hepatocellular research program: (A) established a clinically relevant molecular classification system capable of predicting recurrence and survival, (B) identified genetic drivers of liver cancer progression that are also targets for therapy, and (C) provided a molecular diagnosis of liver cancer. We have now begun to study another refractory cancer that affects the liver and bile ducts called intrahepatic cholangiocarcinoma (ICC). The causes and treatments of ICC are poorly understood and this represents an unmet medical need. The SWCRF has provided essential support that has made possible our work to treat these deadly cancers.

ALL CANCERS

Ronald M. Evans, Ph.D., Salk Institute
Reuben Shaw, Ph.D., Salk Institute

Our work supported by the Waxman Foundation is focused on genetic pathways which are a normal part of how cells regulate their metabolism, but these same genes can contribute to cancer when deregulated. Altering one of these pathways in mice causes colon cancer when exposed to cancer causing agents, but only when fed a high fat diet along with abnormal bile acid production. This leads to bacterial overgrowth and inflammation that fuels the cancer cells in the presence of a high fat diet. Another central metabolic pathway we investigated activates a metabolic switch in the cell to reprogram cell growth and metabolism when nutrients or cellular energy is limited. This pathway is altered in diverse cancers, most notably in 30% of lung cancers. We are exploring ways to target different cancer types using metabolic therapeutics based on our developing knowledge of the intricacies of the pathways.
BLOOD MALIGNANCIES
Ravi Bhatia, M.D. City of Hope
Brad Cairns, Ph.D. University of Utah
Sai-Juan Chen, M.D., Ph.D. Shanghai Institute of Hematology
John D. Crispino, Ph.D. Northwestern University
Margaret Goodell, Ph.D. Baylor College of Medicine
Scott Hebert, Ph.D. Vanderbilt University
Yongkui Jing, Ph.D. Mount Sinai School of Medicine
David A. Jones, Ph.D. University of Utah
Ross Levine, M.D. Memorial Sloan Kettering
Jonathan D. Licht, M.D. Northwestern University
Ari Melnick, M.D. Weill Cornell Medical Center
Warren Pear, M.D., Ph.D. University of Pennsylvania
Ruibao Ren, M.D., Ph.D. Brandeis University
Erwin G. Van Meir, Ph.D. Emory University School of Medicine
Samuel Waxman, M.D. Mount Sinai School of Medicine
Arthur Zelent, Ph.D. Institute of Cancer Research

BRAIN CANCER PROGRAM
Albert S. Baldwin, Jr., Ph.D. University of North Carolina, Chapel Hill
Mark Lemmon, Ph.D. University of Pennsylvania
Kevan Shokat, Ph.D. University of California, San Francisco
William Weiss, Ph.D. University of California, San Francisco

BREAST CANCER PROGRAM
Alan Ashworth, Ph.D. Institute of Cancer Research, London
Albert S. Baldwin, Jr., Ph.D. University of North Carolina, Chapel Hill
Stephen Baylin, M.D. Johns Hopkins University
Robert A. Casero, Ph.D. Johns Hopkins University
Eduardo Farias, Ph.D. Mount Sinai Medical Center
Doris Germain, Ph.D. Mount Sinai Medical Center
Wilson Miller, M.D. Jewish General Hospital
Samuel Waxman, M.D. Mount Sinai Medical Center
Robert A. Weinberg, Ph.D. Whitehead Institute for Biomedical Research
Cynthia Zahnow, Ph.D. Institute of Cancer Research
Arthur Zelent, Ph.D. Institute of Cancer Research, London
Ming-Ming Zhou, Ph.D. Mount Sinai School of Medicine

CANCER STEM CELL PROGRAM
Julio Aguirre-Ghiso, Ph.D. Mount Sinai Medical Center
Nabeel Bardeesy, Ph.D. Massachusetts General Hospital
Stephen Baylin, M.D. Johns Hopkins University
Ravi Bhatia, M.D. City of Hope
Robert A. Casero, Ph.D. Johns Hopkins University
Margaret Goodell, Ph.D. Baylor College of Medicine
Benjamin G. Neel, M.D., Ph.D. Ontario Cancer Institute
Yolanda Sanchez, Ph.D. Dartmouth School of Medicine
Robert A. Weinberg, Ph.D. Whitehead Institute for Biomedical Research
Cynthia Zahnow, Ph.D. Johns Hopkins University

CHILDHOOD AND YOUNG ADULT CANCERS
Albert Baldwin, Jr., Ph.D. University of North Carolina, Chapel Hill
James E. Bradner, M.D. Dana-Farber Cancer Institute
Anthony Capobianco, M.D. University of Miami
John D. Crispino, Ph.D. Northwestern University
Alan Friedman, M.D. Johns Hopkins University
Christopher A. French, M.D. Brigham and Women’s Hospital
Shai Izraeli, M.D. Tel Aviv University
Scott Hebert, Ph.D. Vanderbilt University
Mark Lemmon, Ph.D. University of Pennsylvania
Kevan Shokat, Ph.D. University of California, San Francisco
Erwin G. Van Meir, Ph.D. Emory University School of Medicine
William Weiss, M.D., Ph.D. University of California, San Francisco

COLON CANCER PROGRAM
Ronald Evans, Ph.D. Salk Institute
Reuben Shaw, Ph.D. Salk Institute
As we go to press with the 2012 annual report, the SWCRF is saddened by the death of one of its most beloved, longest and devoted donors. Even in his last days, Abby with his wife Mildred Levine took the time to write the following in support of their firm belief and commitment to the Foundation:

“We are very proud to be so strongly involved with the SWCRF for over 30 years. We endorse the Foundation’s leadership, vision, and the collaborative approach to ‘finding a cure’ which will benefit all humanity. We applaud the Foundation’s deep commitment and dedication to furthering cancer research and developing cures. We believe in the future accomplishments of the Samuel Waxman Cancer Research Foundation and plan to continue our support.”

We thank you Abby, for your continuous commitment to furthering cancer research and developing cures. You have benefited all humanity with your dedication and generosity.
Dale and Peter Claman
Ms. Kemberly Danner
Mr. and Mrs. Scott Eichel
Estate of Adele Bozio
Anonymous
Good Hill Partners
Hatteras Financial Corporation
Mr. Gary Jacob
Mr. Mike Joo
Mr. and Mrs. Howard Kurz
The Litwin Foundation
Mr. Thomas Marano
Mr. John McNiff
Mr. Matthew McQueen
Mr. and Mrs. Robert Michiels
Mr. and Mrs. Randal A. Nardone
Mr. and Mrs. Craig Overlander
Mr. and Mrs. Adam Siegel
The Alan B. Slifka Foundation
Mr. Thomas Marano
Mr. and Mrs. Joseph G. Steffa, Jr.
Sun Capital Partners, Inc.
Mr. and Mrs. Laurence Tarica
Titan Advisors, LLC
Bettina and Spencer Waxman
Mr. and Mrs. Joshua B. Weintraub

$10,000 - $19,000

Mr. and Mrs. Joseph Ades
AGNC
Anileh Ahuja
Angelo, Gordon & Co.
Ms. Bridget Bartlett
Erin and Peter Bartlett
Mr. and Mrs. David B. Benham
Bingham McCutchen LLP
Mr. and Mrs. Brian Bornstein
Mr. and Mrs. John D. Brewer, Jr.
Cadmalader, Wickesham & Taft
Mr. Thomas J. Carroll
Mr. and Mrs. Matthew Chasin
Mr. and Mrs. Peter Cherasia
Mr. Steven Choran
Citi Business Services
Mr. Michael Commaroto
CRT Capital Group
Mr. and Mrs. Mark Davies
Mr. David Dietche
Mr. Michael Dubno
The Durst Organization Inc.
EverBank

Mr. Kenneth Fishel
Mr. Christopher Flanagan
Dr. Roger Gilbert
Glenwood Management
Ms. Sylvia Golden
Mr. and Mrs. Clifford Greenberg
Ms. Felicia Grumet and Mr. Mitchell Levine
Mr. W. David Hinkelman
ICAP Services North America LLC
Mr. and Mrs. Marshall Insley
Jefferies & Company, Inc.
The Drew Katz Foundation
Mr. and Mrs. Bernard Kaminsky
Mr. Joseph Klinow
Mr. Kristopher Konrad
Stuart and Jennifer Kronick
Howard Kurz Family Foundation
Mr. Matthew Lambiase
Mr. and Mrs. Keith Lind
Mr. and Mrs. Leonard Litwin
Mr. Joe Lizio
Mr. and Mrs. Jeffrey Mayer
MFA Financial Inc.
Dana and Michael Miller
Corrie Nichols
Options Group
Orrick, Herrington & Sutcliffe LLP
Palm Bay International
Mr. Randy Reiff
Mr. and Mrs. Robert J. Richter
Mr. and Mrs. Elihu Rose
Mr. Andrew Sabin
Mr. Brad Scott
Mr. George Sherman
Mr. and Mrs. Andrew Sloves
Mr. and Mrs. Richard Spitz
Mr. Eric Szabi
Mr. and Mrs. Marc D. Taub
Mr. and Mrs. David S. Taub
Mr. James C. Weakley and Ms. Maria T. Poli
Norman and Rosita Winston Foundation
World-Wide Holdings Corporation
Mr. and Mrs. Robert Yaffe
Mr. and Mrs. Matthew Zisette

$5,000 - $9,999

Mr. and Mrs. Bret Ackerman
Albanese Organization
Mr. Jonathan Allen
Mr. Gregg Allman
Ms. Miriam Ament
Mr. and Mrs. William Arnold

Mr. Abner Golieb
Mr. and Mrs. Jay G. Axelrod
Barclays North America
Mr. and Mrs. Theodore Breck
Capital One
Mr. and Mrs. Maurice J. Cohn
Mr. Wynne Comer
Coyne Family Foundation
Mr. Robert Darwin
Mr. and Mrs. Tom Duda
Mr. and Mrs. Brad Egna
Mr. and Mrs. Robert Eichler
Mr. Jesse Elhai
Mr. and Mrs. Joseph Feshbach
Mr. and Mrs. Robert Fishbein
Mr. and Mrs. Andrew Friedwald
Mr. Christopher Garvie
Mr. and Mrs. Bill Gibbs
Jeffrey and Laurie Goldberger
Mr. Robert M. Grillo
Mr. and Mrs. Peter S. Grouev
H/2 Capital Partners
Mr. Philip Ha
Mr. and Mrs. Dennis A. Herman
Mr. Michael Hokin
Mr. Timothy Jay
Mr. Brian F. Kane
Mr. Bob Karner
Ms. Tracey Keegan
Willis King
Mr. Dan Kleiman
Mr. Dylan Korpita
Mr. and Mrs. Josh Kuriloff
Mr. Michael Lehman
Mr. Robert I. Lipp
M & T Bank
Mr. and Mrs. Satish M. Mansukhani
Mr. and Mrs. Steve Mayer
Mr. Peter McCubbin
Ms. Nancy McLarnon
Ms. Megan Messina
Mr. and Mrs. Ira Nierenberg
Mr. Michael O’Leary
Mr. Jason Ourman
Mr. Nilam R. Patel
The Pere Partnership, Inc.
Mr. Perry Rahbar
Mrs. Rashaan Reid
Mr. Mark Rosen
Mr. and Mrs. John Ryan
Mr. and Mrs. David Sachs
Mrs. Leah P. Sanzari
Mrs. Edwin C. Scheurer
Mr. and Mrs. Greg Schwab
Mr. and Mrs. Jonathan Sebiri
Mr. and Mrs. Thomas Shea
Mr. and Mrs. Tony M. Shogren
Mr. Richard Sigg
Kirat Singh
Mr. and Mrs. Marc Spilker
Mr. and Mrs. Ben Todres
Mr. Marc J. Toscano
Mr. and Mrs. Joseph F. Valentine
Ms. Cornelia Von Rittberg
Dr. and Mrs. Samuel Waxman
Mr. and Mrs. Stephen Weinstein
Mr. Aaron Welsh
Mr. Mitchell Winter
Mr. and Mrs. Joe Woodstock

$1,000 - $4,999

Mr. Jeffrey Abend
Mr. and Mrs. Steven Abrahams
Mr. and Mrs. Myron Adler
Ms. Kristen Landino and Mr. Vikrant Agnihotri
Mr. Kevin Alexander
Mr. and Mrs. Lee Alper
Mr. and Mrs. Lawrence Altman
Jack & Mimi Amsterdam Foundation
Mr. and Mrs. Carl Anderson
Anonymous
Mr. Ryan Asato
Mr. and Mrs. Andrew M. Assael
Mr. and Mrs. Branden Avishar
Mr. and Mrs. Jonathan E. Babkow
Bank of America United Way Campaign
Ms. Holly Bard
Dr. Lou H. Barnett
Mr. and Mrs. Frederick W. Barney, Jr.
Chris Barratt
Anonymous
BC International Group, Inc.
Mr. and Mrs. Timothy Beaulac
Steven and Penny Beberman
Mr. Bade Benabdessadek
Mr. and Mrs. Howard Berkenfeld
Mr. and Mrs. Mark C. Biderman
Mr. Bill Birnbaum
Mr. Erik Bisso
Black Fleece by Brooks Brothers
Mr. Charles Bloom
Bloomingdales
The Jonathan and Sara Bonesteel Foundation
Mr. Gregory A. Bonsignore
Mr. Tom Boran
Mr. Rich Boyd
Brescome Barton
Mr. and Mrs. Fred Brettschneider
Mr. and Mrs. Daniel Brodsky
Mr. George K. Brommer, III
Ms. Sheri Bronstein
Mr. Dan Bruckner
Mr. and Mrs. Peter M. Brunell
Mr. Robert Caldwell
Ms. Mary Anne Callahan
Mr. Ted Campbell
Mr. Joseph Campise
Bonnie and David Cantor
Cantor Fitzgerald Securities
Ms. Gina Carbone
Mr. George Carp
Mr. Jim Carroll
Mr. and Mrs. Joseph Ceccarini
Mr. and Mrs. Phil Cedar
Mr. and Mrs. Danny Chestler
Mr. Clarence Chia
Mr. and Mrs. Samuel S. Choi
Ms. Jisook Choi
Mr. Lance Choos
Mr. and Mrs. Marvin Chadnoff
Mr. and Mrs. David Cohen
Mr. Thomas Coleman
The Natasha Comfort Community Gifts Fund
Mr. and Mrs. Thomas A. Conway
Mr. Noah Cooper
Mr. Marc Correra
Mr. Donald J. Corsaro
Mr. TC Cosby
Cosentini Associates
Mr. Ryan Craft
Mr. David H. Crean
Mr. and Mrs. Richard J. Crescenzo
Mr. Apurva Dabholkar
Mr. Rafic Dahan
Mr. Dennis C. Delaney
Mr. Ravi Desai
Ms. Rosemarie Di Lorenzo
Mr. Frank DiBartolo
Mr. and Mrs. Robert L. Dillmeier
Dr. and Mrs. Ethan Dmitrovsky
Mr. Thomas J. Doherty
Ms. Adina Dolfman
Mr. and Mrs. Ted Donohue
Dr. Kathy Drill
Mr. Ryan Driscoll
Dr. Susan Grossman and Mr. Adam Sokoloff
Mr. and Mrs. C. Correll Durling
Mr. and Mrs. Jim Egan
Mr. Blake Eger
Mr. and Mrs. Richard A. Eimbinde
Mr. and Mrs. Robert Elman
Mr. and Mrs. Robert Engelking
Ms. Jayne Fagas and Mr. Paul Strauch
Mr. David Fallick
Mr. Timothy P. Fallon
Ms. Karen X. Fang
Mr. Peter Federico
Mr. Jeffrey Feil
Mr. Leonard Fichter
Mr. Joseph P. Finnerty
Mr. David Flannery
Mr. Barry Fleck
Mr. Grant Follansbee
Mr. Antonio Franco
Mr. and Mrs. James E. Frankel
Mr. and Mrs. Ronald A. Freydberg
Mr. and Mrs. Robert Friedman
Mr. and Mrs. Paul Friedman
Mr. Daniel Frommer
Fusion Analytics
Mr. Ronald Gargiulo
Mr. Kevin Gately
Mr. Robert A. Gay
Ms. Jeanmarie Geniers and Mr. Paul Josling
Mr. Gary Gladstein
Glatzer’s
Mr. and Mrs. Andy Glenn
Mr. and Mrs. Seth Glickenhauser
Mr. Graham C. Goldsmith
Mr. Kevin Goldstein
Leslie Goldwasser
Mr. and Mrs. Steven Gordon
Gosset Champagne
Gotham Construction
Mr. and Mrs. Paul Greenfield
Mrs. Susan Greenfield
Mr. and Mrs. Barry L. Grieff
Dr. and Mrs. Jeffrey Gropper
Mr. and Mrs. Edgar Gross
Mr. Mohil Gupta
Mr. Ajit Gupta
Mr. Stephen Harris
Mr. and Mrs. Patrick Higgins
HINT
Mr. and Mrs. Ed Hochstadter
Samuel and Hannah Holzman Trust
Mr. and Mrs. Michael Hubbe
Mr. Seth Jackier
Mr. Max K. Jaeger
Mr. and Mrs. Allen Jaffy
Florence and Evan Janovic
Ms. Kushmaotee Gujadhur and Mr. Gyan Sinha
Mr. and Mrs. Walter Small
Mr. Steve Smallowitz
Ms. Paula Smith
Mr. David Sobotka
Mr. and Mrs. Michael Sokol
Mr. and Mrs. Richard Solomon
Mr. Jerome S. Solomon
Solow Realty & Development Company LLC
Mr. Vincent J. Sottile
Mr. Matthew Spoerlin
Mr. and Mrs. Martin St. Pierre
Ms. Deborah Stanko
Mr. and Mrs. Steven Starker
Mr. Dale Stavin
Mr. and Mrs. Robert Steiner
Mr. and Mrs. Clifford A. Sterling
Mr. Stanley Stern
Ms. Mary Stone
Mr. and Mrs. David Stone
Mr. and Mrs. Sean Sullivan
Mr. Gary Swidler
Swimwear Anywhere
Mr. Conor Taniguchi
Mr. Edward Tappan
Mr. and Mrs. Chal Taylor
Ms. Cynthia Temple
Mr. and Mrs. Steven Tishman
Mr. Alan Todd
Mr. Declan Turner
Mr. and Mrs. John Twyman
Mr. and Mrs. Alan L. Tyson
Mr. David S. Sanders
Ms. Carol F. Venezia
Mr. Subra Viswanathan
Mr. Christopher Walcott
Mr. and Mrs. Michael Walmack
Mr. Mike Wassong
Mr. and Mrs. Scott Waxman
Mr. Bryan Weadock
Ms. Evelene Wechsler
Mr. Neil Weidner
Mr. and Mrs. Michael Weinbaum
Ms. Adele Weiner
Carole and Marcus Weinstein
Wells Fargo
Ms. Leah Wenger
Western Carriers Inc.
Mr. and Mrs. Dale P. Westhoff
Mr. Jim Whittinger
Mr. and Mrs. Paul Whitman
Mr. and Mrs. Richard Wilpon
The Wistar Institute
Cindy and David Wittels
Dr. and Mrs. Richard A. Wolff
Mr. and Mrs. Jeffrey Wray
Mr. and Mrs. F. Kelly Wright
Jennifer and Keith Yanowitz
Ms. Janet Yaseen Kaplan
Janet Yaseen Foundation
Ms. Brittain Youngblood
Dr. Hua E. Yu and Dr. Richard Jove
Mr. Daniel Ziluca
Mr. and Mrs. Soofian Zuberi

$500 - $999
Hayley and Warren Alstodt
Arloetta Food Studio
Ms. Christine Arlotta and Mr. Mario Pecoraro
Mr. Bob Baggett
Mr. and Mrs. Shlomo Bakhash
Mr. Gerald Barad
Ms. Rosalind Devon and Mr. Sanford Batkin
Mr. and Mrs. Bradford Benjamin
Biondo & Hammer, LLP
Ms. Monica Jacobson and Mr. Arnold Bressler
Ms. Grace Brod
Mr. Christopher Burnett
Mr. Ezra Chammah
Mr. Alexander M. Chudnoff
Paula and Richard Cohen
Mr. and Mrs. Richard Crystal
Mr. and Mrs. Paul Dietche
Ms. Amy Dieterich
Mr. Brendan Donnelly
Empire Office
Ms. Dasha Epstein
Mr. and Mrs. William Ettelson
Ms. Beth Farber
Mr. and Mrs. Jack Feuer
Mr. Quentin Fogan
Mr. and Mrs. Barry R. Frankel
The Honorable Judith Gische
Mr. and Mrs. Simeon Gold
Dr. Joel Goldberg
Mr. Jeffrey Goldshein
Mr. and Mrs. Robert J. Goldstein
Mr. Marc J. Goldstein
Mr. and Mrs. Scott Hansen
Ms. Adrienne Gordon and Mr. Gary Herman
Mr. and Mrs. Stuart Israel
Mr. Christopher Jonas
The Jones Group
Mr. and Mrs. Bill Joseph
Mr. Adam Kamenstein
Mr. and Mrs. Marc Kaplan
Mrs. Iris Keltz
KlingerVision
Ms. Tatiana Kotchoubey
Mr. Morris Kramer
Mr. and Mrs. Shawn P. Landau
Sandy and Michael Lavipour
Ms. Berta Lavipour
Mrs. Phyllis Leventhal
Ms. Laila Levitas
Mr. and Mrs. Bruce A. Lieberman
Mr. and Mrs. Sam Linder
Mr. Kevin Ling
Mr. Gerald Little
Ms. Elaine Lovell
Ms. Penni Ludvig
Mr. Matthew Mallgrave
Ms. Diane Matsuki
Mr. and Mrs. George W. McDowell
Mr. John McGuire
Mr. Ron Meier
Mrs. Gail and Allen Meisel
Mr. Craig M. Meltzer
Ms. Joyce Menschel
Ms. Marilyn Monter
Mr. and Mrs. Alan Morris
M.S. Walker
Mr. and Mrs. Norman Nierenberg
Mr. Michael Norris
Old Oaks Foundation
Mr. and Mrs. Stephen J. O’Neil
Mr. and Mrs. Jordan Ouida
Parkside Printing
Mr. Richard Passer
Mr. Gregory Petrie
Mr. Dennis B. Porter
Ms. Susan Preslier
Mr. Philip Ratus
Judith and Donald Rechler Foundation
Mr. Dean Roberson
Mr. and Mrs. Yaron Rosenthal
Mr. Edward M. Sadovnik
Mr. and Mrs. Lawrence Saidenberg
Mr. and Mrs. Morris Sarna
Ms. Audrey A. Schein
Mr. Michael Schwartz
Mr. and Mrs. Jerome Shapiro
Ms. Linda Shapiro
Mr. and Mrs. Irwin Siegel
Mr. and Mrs. Robert Skollar
Mr. Daniel Sagg
Sun Capital Partners Foundation, Inc.
Temple Emanu-el
GIFTS WERE MADE IN MEMORY OR IN HONOR OF:

Connie Aronson
Madlyn Barnett
Bonnie Bartlett
Pat Bell’s Sister
Catherine Bennet
Tomi Berney
Tricia Black
Ruth Bodzy
Dolly Brickman
Rose Brody
Michael Burkhardt
Andrea F. Carret
Peter Claman
Dale Claman
Cris Cleland
Charles Corum
Robert Davis
Philip Davis
David Didona
Rhoda Dorsky
Doris Farber
Michael A. Farrell
Beth Feiwell
Beth Feiwell Family
Elliot I. Fishkin
Tara Fitzgerald
Mark J. Fizulich
Barry Fritz
Nancy Gilbert
Judi Gladstein
Marsha L. Gladstein
Hilda Glantz
Stanley Goodman
Milton Greenberg
Sara Lavipour Hansen
Patricia Hayden
Donald Helfman
Sally Herwitz
Lillian Hirsch
Rita Horen
Bernard Issacs
Joseph Janovic
Ye Jiazhi
Kenneth Joseph
Adrienne Kantor
Rachel Katz
Carole Kaye
Eric L. Kriftcher
Noel Kriftcher
Marcia Lavipour
Abner Levine
Harriet Lewis
Jenny McDevitt
Jessica Meier
Richard Milrad
Jean Nichols
Michael B. Nierenberg
Salvatore Pecoraro
Phyllis Pickholz
James Rapaport
Robert Rizzo’s Mother
Lindsay Rodman
John Rosenberg
Samuel Roth
Robert Sabin
Laurie Schaffran
Edwin C. Scheurer
Daniel Schwab
Lisa Scudder
Alfred J. Seaman
Neil Seiden
Joseph Shea
Daniel Shea
Edward Sheldon
Opal Shinn
Mayer Siegel
Daniel Siegel
Baron Silverstein
Pamela Simmons-Beasley
Carole Sklar
Earl Stich
Zdzislawa M. Szadkowski
Fred B. Tarter
David S. Taub
Leonard Walker
Jessica Warner
Samuel Waxman
Marion Waxman
Walter J. Webb
Connie Webb

Jessenawa Werner
Bill Wiley
Marvin Wolovnick
David Worthman
Jennifer Yanowitz
Alex B. Zerden

A NOTE TO OUR SUPPORTERS

We have carefully reviewed all gifts made to the Samuel Waxman Cancer Research Foundation to ensure each gift is properly recognized. The Thank You list includes all gifts made between January 1, 2012 and December 31, 2012. Gifts mentioned exclude in-kind donations.

We make every effort to follow the donor’s preferences when compiling the annual report list. If you would prefer to have your name listed differently in the future, please let us know. If we have made a mistake, we sincerely apologize for our error and ask you to bring it to our attention. Please contact Jay Camp at 646-398-5260 so the record may be corrected. Thank you.

Photo credits:
Gala: Rebecca Weiss Photography
Hamptons Happening: Society-in-Focus
Golf Tournament: Michael Priest Photography
Others: Danny Wilcox Frazier
### REVENUE

<table>
<thead>
<tr>
<th>Revenue Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$425,000</td>
</tr>
<tr>
<td>Program Grants</td>
<td>$1,380,000</td>
</tr>
<tr>
<td>Fundraising Income</td>
<td>$2,990,000</td>
</tr>
<tr>
<td>Investment Income</td>
<td>$125,000</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td><strong>$4,920,000</strong></td>
</tr>
</tbody>
</table>

### EXPENSE

<table>
<thead>
<tr>
<th>Expense Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$3,737,000</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$943,000</td>
</tr>
<tr>
<td>Management and General</td>
<td>$433,000</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td><strong>$5,113,000</strong></td>
</tr>
</tbody>
</table>

### SURPLUS/(DEFICIT)

<table>
<thead>
<tr>
<th>Surplus/(Deficit)</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surplus/(Deficit)</strong></td>
<td><strong>$(193,000)</strong></td>
</tr>
</tbody>
</table>

(Year: July 1, 2012 – June 30, 2013 unaudited)
SAMUEL WAXMAN
CANCER RESEARCH FOUNDATION

CHAIRMAN
Michael Nierenberg

FOUNDER & SCIENTIFIC DIRECTOR
Samuel Waxman, M.D.

PRESIDENT & TREASURER
Thomas A. Conway

VICE PRESIDENTS
Spencer Waxman, Dena K. Weiner

SECRETARY
Laurie L. Schaffran

BOARD OF DIRECTORS
David B. Benham, Dale Claman, James E. Frankel, Gary Gladstein, Clifford Greenberg,
Dennis A. Herman, Linda Herman, David Hinkelman, Alissa Jacob, Gary Jacob, Robert Kantor,
Howard Kurz, Matthew Lyons, Riva Ariella Ritvo-Slifka, Howard Shlafmitz, Tony M. Shogren,
Clifford Sterling, David S. Taub**, Samuel Waxman, M.D.

HONORARY BOARD
Maureen Cogan, Martin L. Coyne, Mary Kantor, Abner Levine**, Mildred Levine, Susan W. Rose, Alan P. Safir *,

CHAIRMAN’S COUNCIL
Lawrence Altman, Peter Claman, Arminio Fraga, Costas Kondylis, Thomas Marano, Bernard Sillins

ASSOCIATE SCIENTIFIC DIRECTORS
Ethan Dmitrovsky, M.D., Jonathan Licht, M.D.

SCIENTIFIC ADVISORY BOARD
Steven J. Burakoff, M.D., Riccardo Dalla-Favera, M.D., Lorraine Gudas, Ph.D., Alan Rosmarin, M.D.,
Nancy Speck, Ph.D., Hua Yu, Ph.D.

FOUNDATION STAFF
Amanda Aronson, Carole Asher, Jay Camp, Gayle Maurin, Bridget Stein

* Past Chair **Deceased